Does Aetna Cover Trulicity? Formulary Status, Prior Authorization, and Cost Breakdown

The short answer, and why this page cannot give you a dollar figure

Aetna, like nearly every major commercial and Medicare Advantage insurer, includes Trulicity on its formularies because it is an FDA-approved, widely prescribed diabetes medication with a large trial base. That part is stable and unlikely to change without a broader shift in diabetes care.

What is not stable, and what we do not have a current Aetna source document for, is which tier Trulicity sits on for your plan, what your copay or coinsurance will be, and whether your plan requires you to try metformin or another drug first. Formulary tiers, cost-sharing amounts, and step therapy rules are set by each plan sponsor for each plan year, and they are exactly the kind of detail that goes stale within months. Rather than presenting specific dollar ranges as if they apply to your plan, this page explains how coverage decisions generally work and tells you where to confirm the current numbers.

How GLP-1 formulary placement generally works

Most commercial insurers place brand-name GLP-1 receptor agonists like Trulicity, Ozempic, and Rybelsus on preferred or non-preferred brand tiers rather than generic tiers, because no generic dulaglutide exists. Preferred brand tiers usually carry a lower copay than non-preferred tiers, and some plans use coinsurance (a percentage of the negotiated price) instead of a flat copay for higher tiers.

Which tier a specific drug lands on for a specific employer or individual plan depends on rebate agreements between the insurer, the pharmacy benefit manager, and the manufacturer. This is a business negotiation that happens every plan year, which is why Aetna's own numbers, not a third-party estimate, are the only reliable answer for your situation. Your plan's Summary of Benefits and Coverage document, available through your employer's benefits portal or by logging into your Aetna member account, lists the current tier and cost-sharing structure for your specific plan.

Medicare Advantage and Part D

Aetna Medicare Advantage plans that include drug coverage, and standalone Aetna Part D plans, also cover Trulicity, with tier placement that can differ from commercial plans and that varies by region and plan year. One federal fact that does apply broadly starting in 2025: the Inflation Reduction Act capped total annual out-of-pocket spending on Part D-covered drugs at $2,000 per year, after which the plan covers 100% of costs for the remainder of the calendar year. This cap is a statutory Medicare feature, not an Aetna-specific policy, so it applies regardless of which tier Trulicity sits on for your plan. You can confirm current Part D rules through CMS (https://www.cms.gov).

Manufacturer copay assistance cards, including Lilly's Trulicity savings program, cannot legally be used by patients on Medicare, Medicaid, or Tricare because of federal anti-kickback rules governing government health programs. That restriction is a matter of federal law and applies to every manufacturer copay program, not just Lilly's.

Prior authorization: what is likely to be true, and what you need to confirm

Requiring prior authorization for GLP-1 receptor agonists is standard practice across most major insurers, Aetna included, given the drug class's cost relative to older diabetes medications like metformin and sulfonylureas. It is reasonable to expect that your prescriber will need to submit clinical documentation before Aetna approves Trulicity, but the exact criteria, whether step therapy applies, and how long a decision takes are set at the plan level and can change each plan year.

Typical documentation insurers request for a GLP-1 prior authorization includes a type 2 diabetes diagnosis, a recent HbA1c value, and a record of prior diabetes medications tried. Some plans require a documented metformin trial (or a documented reason it was not tried) before approving a GLP-1. Ask your prescriber's office to submit this information up front rather than waiting for a request, since incomplete documentation is a common reason authorization requests stall.

Standard and expedited turnaround times for prior authorization decisions are governed partly by state insurance regulations, which vary by state, and partly by plan design. Rather than quoting a single number that will not hold for every state and plan, ask your prescriber's office or Aetna's member services line what the current turnaround commitment is for your plan.

The American Diabetes Association's 2024 Standards of Care lists GLP-1 receptor agonists as a preferred option after metformin for patients with established atherosclerotic cardiovascular disease, and as a reasonable option for many other patients with type 2 diabetes, which is the clinical basis insurers point to when justifying coverage with authorization conditions attached [1].

The clinical evidence behind Trulicity's use in type 2 diabetes

The AWARD program

Dulaglutide's efficacy data comes primarily from the AWARD series of randomized trials. AWARD-1 (N=978) found that dulaglutide 1.5 mg reduced HbA1c by 1.51 percentage points at 26 weeks, compared with 0.99 points for exenatide twice daily and 0.46 points for placebo, when added to pioglitazone with or without metformin [2]. AWARD-5 (N=1,098) compared dulaglutide against sitagliptin over 52 weeks and found a larger HbA1c reduction with dulaglutide 1.5 mg (1.10 points) than with sitagliptin (0.32 points) [3].

REWIND and the cardiovascular indication

The REWIND trial (N=9,901) is the basis for dulaglutide's cardiovascular risk reduction indication. It enrolled a broader population than most cardiovascular outcome trials in this drug class: roughly a third of participants had established cardiovascular disease at baseline, with the rest enrolled based on cardiovascular risk factors alone. Over a median follow-up of 5.4 years, the composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (hazard ratio 0.88, 95% CI 0.79 to 0.99) [4]. Because REWIND enrolled patients both with and without prior cardiovascular events, the FDA's 2020 label expansion for cardiovascular risk reduction applies to a broader population than trials limited to secondary prevention alone [5]. This trial result, not a specific insurer policy, is the clinical justification prescribers typically cite when requesting coverage for a patient with cardiovascular risk factors.

You can confirm dulaglutide's current FDA-approved indications, including any changes since this page was written, through the FDA's Drugs@FDA database [6].

How Trulicity compares with other GLP-1 options Aetna may cover

Aetna's commercial formularies generally include more than one GLP-1 receptor agonist: Trulicity, Ozempic (semaglutide), Rybelsus (oral semaglutide), and Victoza (liraglutide) are common examples, though which ones appear and at what tier depends on the plan. Which drug a plan prefers is driven mainly by rebate negotiations rather than head-to-head efficacy data.

Where efficacy comparisons exist, they can matter for exception requests. The SUSTAIN-7 trial (N=1,201) compared semaglutide against dulaglutide at matched dose steps over 40 weeks and found greater HbA1c reduction and more weight loss with semaglutide at the doses tested [7]. If your plan prefers a different GLP-1 than the one your doctor wants to prescribe, this kind of trial data can support a formulary exception request, but the ADA's 2024 Standards of Care do not rank individual GLP-1 agents in a strict hierarchy and instead recommend individualizing the choice based on cardiovascular risk, weight goals, and injection frequency preference [1].

Coverage limits: Trulicity is not approved for weight loss alone

Trulicity's FDA approval covers type 2 diabetes and, separately, cardiovascular risk reduction in adults with type 2 diabetes. It does not carry an FDA approval for weight management in people without type 2 diabetes, which is the approval that Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) hold [5]. A request for Trulicity for weight loss alone, without a type 2 diabetes diagnosis, is likely to be denied as outside the approved labeling, and that is a coverage limitation tied to the drug's FDA approval rather than an Aetna-specific policy choice.

If a claim or prior authorization request is denied

Standard next steps after a denial include a peer-to-peer review, where your prescriber discusses the clinical rationale directly with a plan medical director, followed by a formal internal appeal if the peer-to-peer does not resolve it. If Aetna upholds a denial after the internal appeal process is exhausted, federal and state consumer protection rules generally give you the right to an external review by an independent third party, whose decision is binding on the insurer. This external review right is a broadly applicable insurance regulation, not something specific to Aetna or to Trulicity.

Kaiser Family Foundation research has tracked how often internal insurance appeals for prescription drug denials get overturned, and the reversal rate that research reports has varied across studies and years. Rather than quoting a single percentage here, check KFF's current published research directly if this figure matters to your decision [8].

Dosing basics, for context

Trulicity is a once-weekly subcutaneous injection given with a prefilled, single-use pen. The FDA label describes a starting dose of 0.75 mg weekly, which a prescriber may increase to 1.5 mg after at least four weeks if more glycemic control is needed. Doses of 3 mg and 4.5 mg were approved in 2020 for patients who need further HbA1c reduction beyond what 1.5 mg achieves [5]. We do not have a verified source in hand for the specific magnitude of additional weight loss at the 3 mg and 4.5 mg doses, so that number is left out here rather than stated without support; ask your prescriber or check the current label for that detail.

The pen is injected in the abdomen, thigh, or upper arm, with the injection site rotated each week, and does not require reconstitution or a separate needle. The label specifies refrigerated storage at 2°C to 8°C, with allowance for room-temperature storage up to 30°C for up to 14 days if refrigeration is not available [5]. Dose changes and injection technique should be directed by your prescriber, not adjusted on your own.

Verification checklist: what is stable versus what you must recheck

Use this to separate facts you can generally rely on from facts that expire and need a current source before you act on them.

Stable facts (federal law or clinical evidence, unlikely to change quickly)

Date-sensitive or plan-sensitive facts (must be reconfirmed, do not rely on this page)

If you are comparing this page against a specific bill, denial letter, or plan document and the numbers do not match what is written above, trust the plan document. This page describes general patterns in how GLP-1 coverage works, not your specific Aetna plan's current terms.